Best Practices in the Multidisciplinary Management of Borderline Resectable and Unresectable Pancreatic Cancer as well as Extrahepatic/Perihilar Cholangiocarcinoma
Pancreato-biliary cancers, mainly pancreatic cancer and extrahepatic cholangiocarcinoma, are almost uniformly fatal malignancies with increasing incidence and poor prognosis even when diagnosed in the early stages of the disease.
Category
  • Gastrointestinal
  • SBRT
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Contemporary FLASH-RT to Its Clinical Translation
FLASH radiation therapy (FLASH-RT), delivered with ultra high dose rate (UHDR), may allow patients to be treated with less normal tissue toxicity for a given tumor dose compared with currently used conventional dose rate.
Category
  • FLASH RT
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
How High Can We Go - How Low Should We Aim? Normal Tissue Dose/Volume Constraints in Lymphoma Radiation Therapy Planning
Normal tissue dose-volume constraints are commonly used for lymphoma radiation therapy (RT) planning.
Category
  • Hematologic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Intersection of Immuno-Molecular-Genetic Profiling and Implications for Immunotherapy (IT) and Immunotherapy-Radiotherapy (IT-RT) Combinations
Although immunotherapy has revolutionized the treatment of cancer, the translation of immunotherapy-radiotherapy (IT-RT) combinations into the clinic has proven challenging.
Category
  • Immunotherapy
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Treatment De-Escalation Strategies for Locally Advanced Rectal Cancer
In the United States, the conventional approach to treating locally advanced rectal cancer has traditionally combined preoperative chemoradiotherapy, total mesorectal excision and adjuvant chemotherapy.
Category
  • Gastrointestinal
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Relevant or Relegated? Radiotherapy for Stage III NSCLC in the Neoadjuvant Era
There are many ongoing advances in the multidisciplinary management of stage III NSCLC, in particular the advent of neoadjuvant immunotherapy in patients who are resectable.
Category
  • Immunotherapy
  • Thoracic
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Sexuality After Cancer Therapy
Patient fertility and sexual complications have few data available from clinical trials. It is noteworthy that the subject is infrequently discussed in institutional peer reviews/ M&M unless there is a Risk Management overlay.
Category
  • Breast
  • Genitourinary
  • Gynecologic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $0.00
Integrating Focal Therapies and Radiation for Enhanced Systemic Immune Modulation
This activity is dedicated to unraveling the emerging field of focal therapies in oncology, with a specific focus on histotripsy, high-intensity focused ultrasound (HIFU) and electroporation.
Category
  • General RO
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Non-Operative Management in Rectal Cancer Contemporary Practice
Modern treatment options such as radiotherapy dose intensification (EBRT boost, brachytherapy or Papillon technique) or additional chemotherapy in total neoadjuvant therapy for rectal cancers have been shown to improve rectal preservation rates better than ever before.
Category
  • Brachytherapy
  • Gastrointestinal
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Evolving Therapeutic Strategies in the Multidisciplinary Management of Patients with Hepatocellular Carcinoma – Improving Outcomes
The management of Hepatocellular Carcinoma (HCC) should be conducted in a multidisciplinary setting to offer individualized therapy. Most patients with HCC are not candidates for curative treatments because of tumor extent or underlying liver dysfunction.
Category
  • Gastrointestinal
  • SBRT
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00

Pages